Peritonitis InfectiousPERIGLUC1NCT03140748
Kinetics of Serum β-D-glucan During Peritonitis With Candida in Resuscitation
A study testing To evaluate the initial levels and kinetics of serum β-D-glucan in people with Peritonitis Infectious and Candida Infection, run by Centre Hospitalier Universitaire, Amiens at 1 site in France.
Trial summary
Intraabdominal fungal infections with Candida are constantly increasing. Their diagnosis and treatment is difficult. Morbidity and mortality are high. Β-D-Glucan has been proposed as a marker of systemic fungal infection in candidemia. Moreover, its kinetics is associated with therapeutic success. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Peritonitis Infectious, Candida Infection
- What is being tested?
- To evaluate the initial levels and kinetics of serum β-D-glucan
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 70 participants
- Where
- 1 siteFrance
- Study dates
- 1 May 2018to 1 Jun 2023
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Major Patient (age ≥ 18 years)
- Community or associated peritonitis, operated and hospitalized in resuscitation
- Affiliation to a social security scheme
Who cannot join
- Allergy known to echinocandins
- Dying Patient
- Limitation of care
- Predictable duration of follow-up ≤ 10 days
- Transfusion within 3 months
- Patient minor, patient under guardianship or curatorship
Trial locations and contacts
1 site in 1 country.
About this study
Intraabdominal fungal infections with Candida are constantly increasing. Their diagnosis and treatment is difficult. Morbidity and mortality are high. Β-D-Glucan has been proposed as a marker of systemic fungal infection in candidemia. Moreover, its kinetics is associated with therapeutic success. On the other hand, there are no data on intraabdominal infections that are much more frequent. The objective of the study is to evaluate the initial levels of β-D-glucan and its daily kinetics during the treatment of fungal peritonitis in resuscitation compared to a control group with a yeast-free peritonitis.
- Conditions
- Peritonitis Infectious, Candida Infection
- Being tested
- To evaluate the initial levels and kinetics of serum β-D-glucan
- Medical subject headings
- Candidiasis
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
To evaluate the initial levels and kinetics of serum β-D-glucanOther
To evaluate the initial levels and kinetics of serum β-D-glucan during fungal peritonitis compared to a control group of yeast-free peritonitis
| Study group | Role | What they receive |
|---|---|---|
| Patients with fungal peritonitis | Other | Not described Receives: Other: To evaluate the initial levels and kinetics of serum β-D-glucan |
| Patients with peritonitis without yeast | Other | Not described Receives: Other: To evaluate the initial levels and kinetics of serum β-D-glucan |
What is being measured
The primary outcome is the main question the study is designed to answer.
Blood determination of serum β-D-glucan kinetics in patients with peritonitis
Blood determination of serum β-D-glucan kinetics in patients with peritonitis
Measured: 28 days
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted4 May 2017
- Study start1 May 2018
- Primary completion22 Aug 2021
- Study completion1 Jun 2023
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Peritonitis InfectiousStudies of the same condition, open and under way.
- More trials run by Centre Hospitalier Universitaire, AmiensThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Screening
- Allocation
- Non-randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 70 participants (actual)
Sponsor and investigators
- Lead sponsor
- Centre Hospitalier Universitaire, Amiens
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03140748
- Sponsor's protocol ID
- PI2016_843_0036
- Acronym
- PERIGLUC1
- Status last verified
- Sep 2025
- First submitted
- 14 Apr 2017
- Last updated
- 19 Sep 2025
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Publications
Dupont H, Malaquin S, Villeret L, Macq PY, Ammenouche N, Tinturier F, Diouf M, Rumbach M, Chouaki T. Is ss-d-glucan Relevant for the Diagnosis and Follow-Up of Intensive Care Patients with Yeast-Complicated Intra-Abdominal Infection? J Fungi (Basel). 2022 May 6;8(5):487. doi: 10.3390/jof8050487.
PubMed 35628743
Study at a glance
From the registry record, last updated by the sponsor on 19 Sep 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Kinetics of Serum β-D-glucan During Peritonitis With Candida in Resuscitation
- ClinicalTrials.gov ID
- NCT03140748
- Acronym / sponsor ID
- PERIGLUC1 / PI2016_843_0036
- Conditions
- Peritonitis Infectious, Candida Infection
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 70 participants (actual)
- Lead sponsor
- Centre Hospitalier Universitaire, AmiensUniversity, hospital or other
- Study start
- 1 May 2018 (actual)
- Primary completion
- 22 Aug 2021 (actual)
- Study completion
- 1 Jun 2023 (actual)
- First posted
- 4 May 2017 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Intraabdominal fungal infections with Candida are constantly increasing. Their diagnosis and treatment is difficult. Morbidity and mortality are high. Β-D-Glucan has been proposed as a marker of systemic fungal infection in candidemia. Moreover, its kinetics is associated with therapeutic success. On the other hand, there are no data on intraabdominal infections that are much more frequent. The objective of the study is to evaluate the initial levels of β-D-glucan and its daily kinetics during the treatment of fungal peritonitis in resuscitation compared to a control group with a yeast-free peritonitis.
Study design
- Primary purpose
- Screening
- Allocation
- Non-randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Patients with fungal peritonitis | Other | Other: To evaluate the initial levels and kinetics of serum β-D-glucan |
| Patients with peritonitis without yeast | Other | Other: To evaluate the initial levels and kinetics of serum β-D-glucan |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (3 listed)
- Major Patient (age ≥ 18 years)
- Community or associated peritonitis, operated and hospitalized in resuscitation
- Affiliation to a social security scheme
Key exclusion criteria (6 listed)
- Allergy known to echinocandins
- Dying Patient
- Limitation of care
- Predictable duration of follow-up ≤ 10 days
- Transfusion within 3 months
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| To evaluate the initial levels and kinetics of serum β-D-glucanTo evaluate the initial levels and kinetics of serum β-D-glucan during fungal peritonitis compared to a control group of yeast-free peritonitis | Other | Patients with fungal peritonitis, Patients with peritonitis without yeast |
Primary outcome
Blood determination of serum β-D-glucan kinetics in patients with peritonitis
Time frame: 28 days
Blood determination of serum β-D-glucan kinetics in patients with peritonitis
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 19 Sep 2025.
- Results publication: PubMed 35628743Dupont H, Malaquin S, Villeret L, Macq PY, Ammenouche N, Tinturier F, Diouf M, Rumbach M, Chouaki T. Is ss-d-glucan Relevant for the Diagnosis and Follow-Up of Intensive Care Patients with Yeast-Complicated Intra-Abdominal Infection? J Fungi (Basel). 2022 May 6;8(5):487. doi: 10.3390/jof8050487.
Related trials for Peritonitis Infectious
Not yet recruiting
Comparative Study Between Laparoscopic and Open Appendectomy of Complicated Appendicitis
Appendicitis, Perforated Appendicitis
RecruitingPhase 2
Prospective, Randomized Trial of Personalized Medicine With Pentaglobin® After Surgical Infectious Source Control in Patients With Peritonitis
Peritonitis, Sepsis
Not yet recruitingObservational study
Saudi Emergency Laparotomy Audit
Laparotomy, Laparotomy Surgery
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing To evaluate the initial levels and kinetics of serum β-D-glucan in people with Peritonitis Infectious and Candida Infection, run by Centre Hospitalier Universitaire, Amiens at 1 site in France.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 19 Sep 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Blood determination of serum β-D-glucan kinetics in patients with peritonitis (time frame: 28 days). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT03140748, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 19 Sep 2025.